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Background: Human T-lymphotropic virus 1 (HTLV-1) has been associated with leukemia/lymphoma (ATL) and
myelopathy/tropical spastic paraparesis (HAM/TSP), in addition to other inflammatory diseases as well as infection
complications. Therapeutic approaches for HTLV-1-related pathologies are limited. The labdane diterpene
myriadenolide (AMY) is a natural product that exhibit biological activities, such as anti-inflammatory and antiviral
activity as reported for HIV and herpesvirus.
Results: We demonstrated that this natural product was able to inhibit the expression of gag-pol mRNA and
substantially reduced the expression of the structural proteins p19 and gp46. Comparison of treated and untreated
cells shows that AMY alters both the morphology and the release of viral particles. The Atomic Force Microscopy
assay showed that the AMY treatment reduced the number of particles on the cell surface by 47%.
Conclusion: We demonstrated that the labdane diterpene myriadenolide reduced the expression of the structural
proteins and the budding of viral particles, besides induces altered morphogenesis of HTLV-1, conferring on AMY a
new antiviral activity that may be useful for the development of new compounds with specific anti-HTLV-1 activity.
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Human T-lymphotropic virus 1 (HTLV-1) is the causal
agent of adult T-cell leukemia (ATL), HTLV-1-
associated myelopathy/tropical spastic paraparesis
(HAM/TSP) and other inflammatory disorders that may
develop after a variable period ranging from months to
decades [1-5].
Decisions regarding ATL treatment should be based on
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unless otherwise stated.disease onset, comorbidities and the response to initial ther-
apy [6]. There was a successful study combining zidovudine
and interferon alpha for ATL and ATL-lymphoma [7], but
the most recent novelty in drugs for ATL is a promising
therapeutic molecule based on a zinc finger nuclease de-
signed to recognize and disrupt the promoter function of
the HTLV-1 LTR and specifically to kill HTLV-1-infected
cells, which was tested in in vitro and in vivo models [8].
Since the discovery of HAM/TSP, various therapeutic
approaches have been used for patients presenting unre-
mitting myelopathic symptoms. However, treatment is
mainly symptomatic, and therapeutic guidelines for
HAM/TSP are missing mainly due to the lack of ran-
domized double-blind controlled clinical trials [9]. Be-
cause induction of chronic inflammation in the spinal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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major pathogenic mechanism underlying HAM/TSP,
anti-inflammatory and antiviral therapies have been
tested [10], and some clinical benefit has been demon-
strated for corticosteroids, mainly oral prednisolone and
intravenous methylprednisolone [11], interferon-α [12]
and IFN-β1 [13]. In a recent study, the evaluation of the
ex vivo and in vitro effects of ascorbic acid and IFN-α
treatment on PBMCs of seronegative, asymptomatic
carriers and HAM/TSP patients demonstrated antipro-
liferative and cell death-inducing and immunomodula-
tory effects of high-dose ascorbic acid [9].
Plants are recognized for their ability to produce a
wealth of secondary metabolites, and many species have
been used for centuries to treat a variety of diseases
[14]. Many of these natural products have been shown
to have interesting biological and pharmacological activ-
ities and are used as chemotherapeutic agents or serve
as the starting point in the development of modern
medicines [15-18]. Alomia myriadenia Schultz-Bip. ex
Baker (Asteraceae) is an herb occurring in the central
regions of Brazil. The ethanol extract of A. myriadenia
contains the labdane-type diterpene myriadenolide (12S,
16-dihydroxy-ent-labda-7, 13-dien-15, 16-olide). Labdane-
type diterpenes are known to occur in terrestrial plants
and marine organisms. They display interesting bio-
logical activities, such as antibacterial, antifungal, anti-
inflammatory, antileishmanial, cardiotonic, cytotoxic
and immunomodulatory activities, and show potential
for use as new drugs [19-24]. Herein, we report evalu-
ation of the antiviral potential of myriadenolide as a
strategy for the development of new therapeutics to
treat HTLV-1-infected patients. We show promising re-
sults for the regulation of viral messengers, expression
of viral proteins, and viral morphogenesis, as evaluated
with transmission electron microscopy (TEM) and atomic
force microscopy (AFM).Figure 1 Effect of myriadenolide on MT-2, Jurkat cells and PBMC viab
24 hours. Cellular viability was inferred by MTT assay. All assays were perfor
Control (Mock sample without DMSO and AMY). Average values with standResults
Measurement of AMY cytotoxicity
To determine AMY cytotoxicity, MT2, Jurkat cells and
human PBMC were treated with 1.0, 0.01 or 0.0001 μM
AMY for 24 hours and the assay results are the mean of
three independent experiments. For human PBMCs, the
assay was performed in triplicate and with peripheral
blood obtained from eight individuals. As demonstrated
in Figure 1, treatment with different concentrations of
AMY did not induce a significant reduction of cell via-
bility in any of the cell types evaluated, compared to the
diluent control (DMSO, 0.005%), showing the safety of
this compound for the cell types tested, including hu-
man PBMCs, used as a control for normal cells.
Quantification of viral mRNA in MT-2 cells after treatment
with AMY
The mRNA levels of the viral genes gag-pol (which encodes
structural proteins and enzymes) and tax-rex (which en-
codes non-structural regulatory proteins) were quantified
in MT-2 after 24 hours of AMY treatment using Real-
Time PCR and were normalized to a cellular housekeeping
gene (GAPDH). The analysis demonstrated that myriade-
nolide was able to inhibit the expression of gag-pol mRNA
at 1 μM of AMY (Figure 2). However, inhibition of tax-
rex mRNA expression was not observed at any concen-
tration tested.
Anti–HTLV-1 Activity of AMY in MT-2 cell line
Western blot assays were performed to determine the ef-
fect of myriadenolide on the expression level of structural
protein p19 (matrix GAG protein) and gp46 (surface ENV
protein) in MT-2 cells after 24 hours of AMY treatment at
varying concentrations (1.0, 0.01 and 0.0001 μM). MT-2
cells treated with AMY showed a reduction in the viral
proteins tested (Figure 3a). It was interesting to observe
that for matrix protein p19 and ENV protein gp46, allility. Cells were treated with 1.0, 0.01 or 0.0001 μM myriadenolide for
med in triplicate in at least two independent experiments. CC – Cell
ard errors (error bars) are presented (GraphPad Prism 5).
Figure 2 Effect of myriadenolide on accumulation of mRNA gag-pol and tax-rex in MT-2. Data represents the relative values of mRNA
estimated by the method of relative quantification using standard curve established with cDNA from untreated MT2 cells (diluent control). Cells
were treated with 1.0, 0.01 or 0.0001 μM myriadenolide for 24 hours. The assays were performed in two independent experiments. *Represents
statistical difference (p = 0.026) between AMY 1 μM and diluent (GraphPad Prism 5; kruskall wallys with Dunn´s post-test).
Figure 3 Expression of viral proteins is reduced in MT-2 cells treated with myriadenolide. MT-2 cells were treated with different concentrations
of myriadenolide (1.0, 0.01 or 0.0001 μM) and viral protein expression was assessed. (a) Monoclonal primary antibodies were used to quantify protein
expression: anti- gp46, p19 and GAPDH. Densitometric analysis was performed on ImageJ software to examine the level of HTLV-1 structural proteins
normalized by GAPDH. (b) Selectivity index was calculated using CC10/EC90 as described in materials and methods. EC = effective concentration;
CC = cytotoxic concentration.
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expression, even at the lowest drug concentration.
In our assays, to determine the selectivity index of
AMY, we choose to use the ratio CC10/EC90 (cytotoxic
concentration – cytotoxicity activity that reduced the
cell viability in 10%/effective concentration - concentra-
tion that reduce the viral protein expression in 90%), as
this is pharmacologically more accurate in evaluating
how safe a compound is as a drug [25]. The EC90 value
of AMY to reduce levels of gp46 and p19 was 0.0001
μM, whereas its 10% cytotoxic concentration (CC10) was
0.0228 μM. Consequently, its selectivity index based on
the ratio CC10/EC90 was 288 (Figure 3b). These results
suggest that AMY has antiviral activity interfering with
the expression of structural proteins of HTLV-1.Figure 4 Transmission electron microscopy of MT-2 cells treated with
AMY. Twenty-four hours post-incubation, cells were stained with uranyl ace
USA). Panels a to c represent MT-2 untreated cells and D to F are MT-2 cel
when compared to mock-treated cells (panels a, b, d and e). HTLV-1 typic
HTLV-1 atypical particles (panel f; arrows) are seen in AMY treated cells. ScaEvaluation of AMY antiviral activity in MT-2 cells using
transmission electron microscopy (TEM) and atomic force
microscopy (AFM)
The TEM and AFM analyses of MT-2 cells were per-
formed 24 h post-incubation in the presence or absence
of 1 μM AMY (Figure 4). Comparison of treated and
untreated cells by TEM shows that treatment with AMY
alters both the release of viral particles and the morph-
ology (emphasized in Figure 4(b)/4(e) and 4(c)/4(f ), re-
spectively). However, we do acknowledge that the TEM
may not be able to precisely determine whether these
are actual complete virus particles or just empty capsids.
Nonetheless, this observation was corroborated using
AFM (Figure 5), and because this technique favors count-
ing the number of particles per field evaluated, it wasAMY. MT-2 cell suspensions were cultivated with or without 1 μM of
tate and examined under a Tecnai G2 F20 electron microscope (FEI,
ls after AMY treatment. Viral budding is reduced in AMY treated cells
al particles are seen when cells are untreated (panel c; arrow) whereas
le bars are represented in each panel.
Figure 5 AFM cell surface scanning of MT2 cells treated with 1 μM and 0.001 μM AMY. The AFM images are phase and amplitude images
and the regions scanned included both cells and matrix, and emphasis was placed on the cell surface. (a) 8.5 μm amplitude image showing the
untreated MT-2 cell; (b) 8.5 μm image of MT-2 cell treated with 0.001 μM AMY; (c) 3.6 μm phase image of untreated MT-2 cells showing budding
events with many virus particles embedded into a matrix; (d) 3.6 μm phase image of MT-2 cells treated with 1 μM AMY showing a flat cell surface
with no virus budding.
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cles on the cell surface by 47%. Of the 412 virus particles
quantified by TEM, 229 viral particles were measured in
cells treated with AMY and 183 in untreated cells. In the
untreated cells, the virus particles ranged from 53 to 212
nm (mean 90.6 nm), and in the treated cells, they ranged
from 41 to 171 nm (mean 91.55 nm). Using AFM, a total
of 158 virus particles were measured (55 and 103 particles
in AMY treated and untreated cells, respectively) and the
size of viruses ranged from 75.8 to 273.6 nm (mean 148.9
nm) in untreated cells, whereas the sizes ranged from 42.4
to 175.5 nm (mean 97.9 nm) in AMY treated cells.
Discussion
HTLV-1 is responsible for inducing a severe myelopathy
and leukemia in humans, in addition to a number of other
inflammatory pathologies for which treatment and thera-
peutic protocols are still ineffective. Consequently, HTLV-
1 is responsible for a significant burden of morbidity andmortality [26]. In the present study, we address the pos-
sible antiviral activity of the labdane-type diterpene
myriadenolide (12S, 16-dihydroxy-ent-labda-7, 13-dien-
15, 16-olide) for HTLV-1. The antiviral activity of the
terpenes has been reported for HIV [27,28] and herpes-
virus [29], among other viruses.
HTLV-1 mainly infects CD4 T cells and deregulates
their differentiation, function and homeostasis, which
may contribute to the pathogenesis of HTLV-1 inducing
chronic inflammatory diseases [30]. HTLV gene products
are engaged in dynamic activating and antagonistic in-
teractions with host cells, mainly driven by the Tax [31]
and HBZ proteins [32]. However, recent mapping of the
HTLV-1 and HTLV-2 host-pathogen interactome showed
that other viral proteins, including Gag and Env from both
viruses, are implicated in a diverse set of cellular processes,
such as the ubiquitin-proteasome system, apoptosis, mul-
tiple cancer pathways and the Notch signaling pathway
[33]. Naturally infected lymphocytes produce virtually no
Martins et al. BMC Microbiology  (2014) 14:331 Page 6 of 10cell-free virions in vivo, and HTLV-1 is transmitted cell-to-
cell through the formation of virological synapses, which
are formed between an infected source cell and a suscep-
tible target cell and play an important role in the spread of
virus in the host [34]. It has also been demonstrated that
there is a rapid transfer of enveloped HTLV-1 particles
across virological synapses [35], reinforcing the idea that
the glycoprotein Env is required for HTLV-1 infectivity
[36]. Before these events, important early steps in the
HTLV-1 assembly pathway include genome recognition
(Gag-RNA interactions), as well as Gag-Gag and Gag-
cellular protein interactions. The Gag polyprotein is
composed of three domains: matrix (MA - p19), capsid
(CA - p24) and nucleocapsid (NC - p15). In later steps
upon budding or immediately after immature particle
release, proteolytic cleavage of Gag polyproteins takes
place and results in virus particle core maturation,
showing that Gag coordinates assembly and viral bud-
ding [37-39]. Taken together, this information about
morphogenesis, viral spread and virus-cell regulation in-
troduces new concepts to target drugs for HTLV-1.
In this context, our results first revealed that the myria-
denolide compound was able to reduce the accumulation
of gag-pol mRNA at 1 μM after 24 hours of treatment (al-
though no variation was seen for tax-rex mRNA in any
concentration tested). HTLV-1 requires regulated gene ex-
pression from unspliced and alternatively spliced tran-
scripts for efficient replication and persistence, being able
to export intron-containing mRNA’s to cytoplasm for sub-
sequent translation, function related to the viral protein
Rex [40]. Rex phosphoprotein acts posttranscriptionally by
preferentially binding, stabilizing, and selectively exporting
the unspliced and incompletely spliced viral mRNA from
the nucleus to the cytoplasm, essentially regulating pro-
duction of the virion components [41]. Experiments con-
ducted with transient transfection of 293T cells with the
HTLV-1 plasmid, as well as newly HTLV-1 infected hu-
man PBMCs, clarified that incompletely spliced (env) and
doubly spliced transcripts (tax/rex) are not generated at
the same rate from full-length transcripts (gag-pol) [42].
Other important point is that unlike the gag/pol and env
transcripts encoding the structural and enzymatic pro-
teins, the efficient expression and cytoplasmic export of
the alternatively spliced regulatory and accessory tran-
scripts are not directly dependent on Rex [40]. However,
the exact mechanism supporting the distinct activity ob-
served upon AMY treatment for gag-pol and tax-rex tran-
scripts remains to be determined. Nonetheless, we could
speculate that phenomenon is based on differential gene
expression regulation and Rex dependence for stability
and transport of the both transcripts.
We observed a significant reduction on p19 and gp46
protein expression when using three different AMY
concentrations (1.0, 0.01 and 0.0001 μM). Curiously thedecreasing concentrations of AMY have increasing in-
hibitory activity on HTLV-1 antigen expression in MT2
cells (Figure 3a). This represents the hormetic dose-
response effect (hormesis), in which a low dose can
define the therapeutic zone (the intended effect, in our
case, antiviral properties). Hormesis is a dose response
relationship in which effects at low doses are opposite to
those at high doses. Recent relevant reports analyzing
hormetic dose responses indicates that this phenomenon
can have specific mechanisms mediated by different re-
ceptors and signaling pathways, having biological diverse
effects in distinct doses [43-45]. Thus, hormesis could
explain why the lowest concentration of AMY (0.0001
μM) was best at reducing viral protein expression. None-
theless, we did not see the same effect when analyzing
transcript levels for the same proteins. At this point we
still do not have a verifiable explanation to this other-
wise biological effect.
The results also emphasize that AMY demonstrated no
cytotoxicity when evaluated at concentrations up to 1 μM,
as previously described by our group [24]. The selectivity
index (288) showed that reduction of viral protein expres-
sion occurs with low toxicity. In drug discovery, it is
desirable to have a high therapeutic/selectivity index (i.e.,
maximum antiviral activity with minimal cell toxicity). An
index higher than 50 is considered as indicative of highly
active compounds [46].
In concert with TEM, which clearly showed differences
in particle morphology in treated and untreated cells
(Figure 4), we used scanning AFM in air tapping mode to
obtain more reliable results for viral particle measurement
and number of budding particles. For untreated cells, the
viruses ranged from 75.8 to 273.6 nm (mean 148.9 nm),
and in treated cells, they ranged from 42.4 to 175.5 nm
(mean 97.9 nm). Experiments using TEM and AFM
proved that treatment of MT-2 for 24 hours using 1.0 μM
myriadenolide was able to reduce the amount of virus at
the cell surface (approximately 47%) and to modify the
morphogenesis of viral particles, in accordance with the
protein inhibition observed in Western blot assays.
Conclusions
These results showed promising anti-HTLV-1 activity,
mainly inhibition of Gag and Env protein expression and
interference in viral budding and morphogenesis. It may
be hypothesized that disruption in viral replication func-
tions could reduce viral spread in infected hosts, suggest-




In this study, MT-2, an HTLV-1-infected T-cell line, and
uninfected Jurkat T-cells were used. For the viability
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(PBMCs) from seronegative blood donors were also
used. Written informed consent was obtained, and this
study was approved by the Ethics Committee of UFMG
and Fundação HEMOMINAS. The cells were maintained
in RPMI-1640 medium supplemented with 10-20% v/v
fetal bovine serum (Life Technologies), 2 mM L-glutamine,
100 U penicillin mL−1 and 50 μg gentamicin mL−1
(SIGMA-ALDRICH).Myriadenolide
Myriadenolide (AMY, Figure 6) was isolated from an etha-
nol extract of aerial parts of Alomia myriadenia Schultz-
Bip. Ex. Baker (Asteraceae) (voucher code BHCB 42865)
as previously described [23]. The AMY compound was
dissolved in DMSO, diluted in RPMI and added to the
culture to attain the desired final concentrations. Control
experiments were performed using DMSO (0.005%).Figure 6 Structure of myriadenolide. This labdane-diterpene was
isolated from Alomia myriadenia (Zani et al. 2000) [23].Cellular viability (MTT assay)
The cytotoxicity was determined in parallel with the
antiviral activity. For that, cell viability was estimated
measuring the rate of mitochondrial reduction of yellow
tetrazolium salt MTT (3-(4.5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide; Sigma-Aldrich, St. Louis,
MO) to insoluble purple crystals [47]. After AMY incu-
bation, MTT solution (20 μL; 5 mg MTT mL−1) was
added to each well and incubated for 4 hours. At the end
of this incubation, the supernatant was removed and 200
μL of 0.04 M HCl in isopropyl alcohol were added to dis-
solve the formazan crystal. The optical densities (OD)
were measured with a spectrophotometer at 590 nm. Re-
sults were normalized with DMSO control (0.005%) and
expressed as percentage of cell viability. Data were ana-
lyzed using Prism 5.0 (GraphPad Software Inc.).
The EC90 was determined as the concentration to re-
duce the viral protein expression in 90% using densitom-
etry (measurement of the density of the viral protein
bands in Western blot assay comparing with the mock
treated cell [diluent control - DMSO 0.005%]) by the
equation: % reduction of viral protein = 100 – (Densi-
tometry values of treated cells ×100)/densitometry values
of the control). The CC10 was defined as the cytotoxic
activity that reduced the cell viability in 10%, and was
measured comparing the treated cell with the mock
treated cell. The equation used was: % reduction of via-
bility = 100 – (Absorbance of treated cells x100)/Absorb-
ance of mock treated cell. The concentrations needed to
achieve 90% of reduction of viral protein expression, i.e,
effective concentration (EC90), as well as the concentra-
tion needed to cause 10% cytotoxicity, i.e, cytotoxic
concentration (CC10) was determinate as described [25].
Antiviral indices or selectivity index (SI) were then cal-
culated as CC10/EC90.
Quantification of gag-pol and tax-rex mRNA expression
RNA was extracted from MT-2 cells using Trizol (Life
Technologies, Carlsbad, CA, USA), and complementary
DNA was synthesized from 1 μg RNA using the High-
Capacity cDNA Reverse Transcription Kit with random
primers (Applied Biosystems, Foster City, USA), accord-
ing to the manufacturer’s instructions. Expression levels
of gag-pol and tax-rex mRNA were quantified using
real-time PCR with serially diluted cDNA (250, 25, 2.5
and 0.25 ng) from HTLV-1-infected MT-2 cells to gener-
ate standard curves, and GAPDH was used as a refer-
ence gene. The amplification reaction for each gene (in
separate tubes) was performed using cDNA synthesized
from 250 ng RNA and 1X SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) in a final
volume of 25 μL with 5 pM of the following primers
according to Li & Green [48]: 5′- ACCAACACCAT
GGCCCA -3′ (sense) and 5′- GAGTCGAGGGATAA
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AGCAAAGGTACTG -3′ (sense) and 5′- AGCCCCCA
GTTCATGCAGACC -3′ (antisense) for gag-pol; and 5′-
ACAGTCAGCCGCATCTTCTT -3′ (sense) and 5′- AC
GACCAAATCCGTTGACTC -3′ (antisense) for human
GAPDH (NM_002046.2). Real-time PCR was performed
in an ABI Prism 7300 Sequence Detector System (Ap-
plied Biosystems, Foster City, CA, USA) with the follow-
ing cycle conditions: 2 min at 50°C and 10 min at 95°C,
followed by 45 cycles of 15 s at 95°C and 1 min at 60°C.
Melting curves were performed after the end of the
amplification cycles to validate the specificity of the
amplified products. All standard dilutions and the con-
trol and individual samples were run in triplicate. Quan-
tification was accepted when standard curves had slopes
between –3.10 and –3.74, and the r2 was >0.99. The ex-
pression of gag-pol and tax-rex mRNA was calculated
using the value of the target gene/value of GAPDH.
Antiviral activity (viral protein reduction by
immunobloting assay)
The antiviral potential of AMY against HTLV-1 was based
on the inhibition of p19 and gp46 viral proteins in per-
manently infected MT-2 cells by immunoblotting analysis.
Briefly, MT-2 cells were treated in the absence (0.05%
DMSO) or presence of AMY for 24 hours (1.0, 0.01 or
0.0001 μM). Cell extracts were prepared using lysis buffer
(50 mM Tris-HCl, pH 7.4, 150 mM sodium chloride,
50 mM sodium fluoride, 10 mM beta-glycerophosphate,
0.1 mM ethylenediaminetetraacetic acid, 10% glycerol, 1%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 2 mM
sodium orthovanadate and 2 mg/ml each of pepstatin, leu-
peptin and aprotinin). Following incubation on ice for 10
min, cell extracts were clarified by centrifugation at 10,000
g for 20 min. Proteins were assayed using the Bradford re-
agent (Bio-Rad, Hercules), and 40 μg of extract from each
sample was resolved by SDS-PAGE and transferred to
nitrocellulose membranes (Bio-Rad Laboratories). Blots
were evaluated using primary anti-HTLV-1 antibodies
(monoclonal anti-p19: sc-57868; anti-gp46: sc-57865 and
anti-GAPDH: sc-66163 from Santa Cruz Biotechnology),
and after incubation with secondary antibody, immunore-
active bands were detected by enhanced chemilumines-
cence according to the manufacturer’s instructions (GE
Healthcare). Densitometric analysis was performed on
ImageJ software.
Transmission electron microscopy (TEM)
MT-2 cell suspensions containing 106 cells/well were
cultivated with or without 1 μM AMY. Twenty-four hours
post-incubation, cells were harvested by centrifugation at
400 g for 5 min at 4°C and washed twice with RPMI. Cells
were collected and fixed in 2.5% glutaraldehyde for 18
hours. After washes in 0.1 M sodium cacodylate, fixedsamples were post-fixed in 1% osmium tetroxide for 30
min. Samples were dehydrated in a graded acetone series
prior to infiltration and embedding (Epon 812 resin). Ul-
trathin longitudinal sections (65 nm) were cut, stained
with uranyl acetate and lead citrate and examined under a
Tecnai G2 F20 electron microscope (FEI).
Atomic force microscopy (AFM) scanning
AFM imaging was performed at room temperature on
equipment monitored by a NanoScope IIId controller
from Bruker AXS (Santa Barbara) operated in tapping
mode and equipped with phase-imaging hardware. Com-
mercial tapping mode tips from MikroMasch (Sofia)
with 230-μm-long cantilevers, resonance frequencies of
60–90 kHz, spring constants of 2.0–5.0 N/m and a nom-
inal tip curvature radius of 10 nm were used. Prior to
microscopy, 13-mm round glass slides were washed ex-
haustively with neutral detergent and incubated in dis-
tilled water at 60°C overnight to remove the remaining
dirt and grease. The glass slides were rinsed again with
cold Milli Q water and subsequently rinsed with 100%
ethanol and dried under laminar flow. After drying, 500
μl 1% poly-l-lysine was added to the slides (SIGMA–AL-
DRICH), and the slides were dried again under laminar
flow. Cleaved mica (Ted Pella Inc) was also used for cell
analysis. MT-2 cells treated with or without 1 μM and
0.001 μM AMY were centrifuged in a cytospin centrifu-
gation apparatus (Jouan) (1000 g, 10 min, 4°C; 5.0 × 105
cells) onto the glass slide or cleaved mica. After centrifu-
gation, the cells were dehydrated successively with 30%,
50% and 70% ethanol. The slides were then fixed with
cold methanol and dried under laminar flow. The AFM
images presented here are phase and amplitude images.
The sizes and heights of structures indicating HTLV-1 on
the surface and viral budding were measured in 5 fields by
glass slide or cleaved mica using the NanoScope software
and Gwyddion software (http://gwyddion.net/) [49].
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